Nightstar Therapeutics PLC (NITE) Expected to Post Earnings of -$0.36 Per Share

Equities analysts forecast that Nightstar Therapeutics PLC (NASDAQ:NITE) will post earnings of ($0.36) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Nightstar Therapeutics’ earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.36). Nightstar Therapeutics reported earnings per share of ($0.52) during the same quarter last year, which would suggest a positive year-over-year growth rate of 30.8%. The business is scheduled to announce its next earnings report on Wednesday, June 5th.

On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.56) per share for the current year, with EPS estimates ranging from ($1.93) to ($1.41). For the next year, analysts expect that the company will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.52) to ($1.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Nightstar Therapeutics.

A number of research analysts have issued reports on NITE shares. Chardan Capital restated a “buy” rating on shares of Nightstar Therapeutics in a research report on Monday, March 4th. Cantor Fitzgerald restated a “buy” rating and set a $42.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, February 26th. ValuEngine upgraded shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research upgraded shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, January 9th. Finally, UBS Group started coverage on shares of Nightstar Therapeutics in a research report on Friday, January 4th. They set a “buy” rating and a $21.00 target price on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $27.06.

Shares of NASDAQ:NITE traded up $0.05 on Thursday, reaching $25.49. 10,174 shares of the company’s stock were exchanged, compared to its average volume of 281,568. Nightstar Therapeutics has a twelve month low of $9.59 and a twelve month high of $29.55. The firm has a market cap of $711.21 million, a PE ratio of -15.63 and a beta of 3.38.

In related news, insider Tuyen Ong sold 2,446 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $25.31, for a total transaction of $61,908.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO David A. Fellows sold 9,305 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $25.31, for a total transaction of $235,509.55. The disclosure for this sale can be found here. Insiders have sold a total of 12,142 shares of company stock worth $307,314 in the last quarter.

A number of large investors have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its stake in Nightstar Therapeutics by 106.7% in the 4th quarter. Squarepoint Ops LLC now owns 43,886 shares of the company’s stock valued at $506,000 after purchasing an additional 22,651 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in Nightstar Therapeutics in the 4th quarter valued at approximately $127,000. Virtus ETF Advisers LLC bought a new position in shares of Nightstar Therapeutics during the fourth quarter valued at $314,000. Marshall Wace LLP bought a new position in shares of Nightstar Therapeutics during the third quarter valued at $1,205,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Nightstar Therapeutics during the third quarter valued at $31,201,000. 39.15% of the stock is owned by institutional investors and hedge funds.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Further Reading: What are gap-up stocks?

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.